Starton Therapeutics Inc CEO Pedro Lichtinger tells Proactive the privately held clinical-stage biopharmaceutical company has formed an exclusive licensing agreement with China-based Haisco Pharmaceutical Group Co Ltd for the development and commercialization of STAR-OLZ, its once-weekly nausea and vomiting treatment.
Lichtinger says STAR-OLZ, a transdermal delivery system of the drug olanzapine, is in development to be the first product approved for PARP inhibitor-induced nausea and vomiting (PIINV). Lichtinger also updated investors on the group's plan to go public.